LIGAND PHARMACEUTICALS INCORPORATED Ligand Pharmaceuticals announced the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer. Mr. Plesha brings to his role more than 30 years of experience in the pharmaceutical industry, including two decades building and leading specialty pharmaceutical commercial organizations. Prior to joining Pelthos, Mr. Plesha was President and Chief CommercialOfficer at BioDelivery Sciences (BDSI) until it was acquired by Collegium Pharmaceutical in 2022.
Under Mr. Plesha?s leadership, BDSI sales grew from $5 million to $160 million. He previously served as Senior Vice President of Gastrointestinal Sales at Salix Pharmaceuticals. During his fifteen-year tenure at Salix, Mr. Pleshaled a nationwide salesforce that grew productsales to more than $1.5 billion annually.
Before Salix, Mr. Plesha was a Regional Sales Manager for Oclassen Dermatologics, a division of Watson Laboratories, and in commercialroles of increasing responsibility at Solvay Pharmaceuticals.
